FindTrial
Sign In

Gut Microbiota, Spark and Flame of COVID-19 Disease

Gut Microbiota, Spark and Flame of COVID-19 Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04355741
Enrollment
115
Registered
2020-04-21
Start date
2020-04-20
Completion date
2020-07-16
Last updated
2020-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Gut microbiota

Brief summary

Elderly, hypertension, diabetes and cardiovascular diseases are risk factors for COVID-19 morbility and mortality. However, the real reason for this is not yet understood. It is well documented that gut microbiota has a critical role in health, particularly in the immune system and therefore, we propose that gut microbiota composition could affect vulnerability and disease outcomes of COVID-19.

Detailed description

In order to explore this hypothesis, we will analyse the gut microbiota of SARSCoV-2 infected patients categorized according to location: \[1\] ambulatory (self-isolation at home), \[2\] ward and \[1\] ICU; and severity.

Interventions

OTHERExposure

Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.

Sponsors

Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental
CollaboratorUNKNOWN
Centro Hospitalar Universitário São João
CollaboratorUNKNOWN
CUF Academic and Research Medical Center
CollaboratorUNKNOWN
Hospital CUF Infante Santo, S.A.
CollaboratorUNKNOWN
Centro de Medicina Laboratorial Germano de Sousa, S.A.
CollaboratorUNKNOWN
CINTESIS - Center for Health Technology and Services Research
CollaboratorUNKNOWN
Universidade Nova de Lisboa
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults of 18 years and above. * COVID-19 patients.

Exclusion criteria

* None.

Design outcomes

Primary

MeasureTime frame
Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.Stool samples of COVID-19 patients will be collected after subject enrollment (single point collection)

Secondary

MeasureTime frame
Differences in gut microbiota composition between COVID-19 patients in relation to mortality.Through study completion, an average of 3 months.
Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.Through study completion, an average of 3 months.
Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.Through study completion, an average of 3 months.

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026